EMA's CHMP recommends approval of six new drugs

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive recommendations for six new medicines at its May meeting.

Among these, the CHMP recommended granting a marketing authorization for privately-held Italian drugmaker Dompé farmaceutici’s Oxervate (cenegermin) for the treatment of moderate to severe neurotrophic keratitis, a rare eye disease that can lead to loss of sight.

There is currently no satisfactory treatment for neurotrophic keratitis. Depending on the stage of their disease, patients may be given eye drops to moisten the eye, antibiotics for eye infections, and protective contact lenses, the CHMP noted. Where appropriate, they may undergo surgery. Oxervate has an orphan designation.